| Dear Fellow Investor, A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda. And they have a clean balance sheet with over $1 billion in cash to fund their efforts. Now, investors are lining up to buy shares. Stock purchases by institutional buyers more than doubled in the last quarter of 2023. What is it about this stock that has everyone excited? "The Buck Stops Here," Dylan Jovine, CEO & Founder Behind the Markets This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe . StockEarnings, Inc |
Today's Bonus Content: Why are the Elites Now Hoarding This One Asset Like Never Before?
No comments:
Post a Comment